Trial of Celecoxib in Amyotrophic Lateral Sclerosis
To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS).
Disease:Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALS
Study Type:Interventional Trial
Study Category:Drug Trial
Study Status:Not enrolling
Study Chair(s)/Principal Investigator(s):
Merit Cudkowicz, Massachusetts General Hospital
Clinicaltrials.gov ID (11 digit #):
Coordinating Center Contact Information
Full Study Summary:
Estimated Study Start Date:06/01/2001
Estimated Study Completion Date:06/30/2003
Posting Last Modified Date:05/09/2019
Date Study Added to alsconsortium.org:05/09/2019
Time since Symptom Onset:
Time since Diagnosis:
Can participants use Riluzole?
- Site Contact Information
Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival. Celecoxib was well tolerated and was not associated with an increased frequency of adverse events. Prostaglandin E(2) levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment.